CpG Locus Methylation Analysis for Colorectal Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting colorectal cancer using methylation analysis are plagued by low sensitivity and specificity due to age-related methylation events and the overestimation of methylation levels, leading to false positives and negatives.
Innovation Solution
The method involves identifying specific CpG loci that are coordinately methylated in adenoma and cancer samples, using a set of marker nucleic acids such as Vimentin, BMP3, Septin9, TFPI2, and EYA4, with bisulfite treatment and digital analysis like sequencing or PCR to determine methylation status, thereby distinguishing between normal and non-normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If methylation analysis is performed using conventional methods, then the detection of cancer is possible, but the sensitivity and specificity are low due to age-related methylation events and overestimation of methylation levels
Solution Approach 1:
The patent segments the methylation analysis by focusing on specific CpG loci within marker genes rather than measuring overall methylation levels. By dividing the genome into specific regions of interest (CpG loci in marker genes like Vimentin, BMP3, Septin9, TFPI2, EYA4) and analyzing them individually, the method achieves higher precision in detecting cancer-specific methylation patterns while filtering out age-related methylation noise.
Solution Approach 2:
The patent applies local quality by examining specific local regions (CpG loci) within marker genes for methylation status rather than measuring global methylation levels. This localized approach allows the method to detect cancer-specific methylation patterns at particular genomic locations, improving both sensitivity and specificity by focusing on biologically relevant regions that are differentially methylated in cancer versus normal tissue.
2Reliability
If methylation analysis is performed to detect cancer, then diagnostic information is obtained, but false positives and false negatives occur due to age-related methylation events
Solution Approach 1:
The patent segments the analysis into specific CpG loci within marker genes that are known to be differentially methylated in cancer. By focusing on these specific segments rather than performing broad methylation screening, the method reduces false positives from age-related methylation while maintaining high sensitivity for cancer detection, thereby reducing both false positive and false negative rates.
Solution Approach 2:
The patent employs feedback mechanisms through the use of marker genes with known methylation patterns in cancer versus normal tissue. By comparing methylation status at specific CpG loci in these marker genes against established reference patterns, the method can feedback-correct for age-related methylation changes and improve diagnostic accuracy, reducing false positives and false negatives.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the sensitivity and specificity of cancer detection by identifying methylation patterns unique to adenoma and cancer cells, reducing false positives and negatives, and providing a more accurate diagnostic tool.
Implementation Method 1
The method involves identifying specific CpG loci that are coordinately methylated in adenoma and cancer samples, using a set of marker nucleic acids such as Vimentin, BMP3, Septin9, TFPI2, and EYA4, with bisulfite treatment and digital analysis like sequencing or PCR to determine methylation status
Data Source
AI summary
The present invention relates to methods and compositions for determination of and uses of specific methylation patterns indicative of adenoma and carcinoma. In particular, the invention relates to analysis of defined CpG loci that are coordinately methylated in DNAs from cancer and adenoma samples, methods for identifying coordinately methylated loci, and methods of using analysis of coordinately methylated loci in one or more marker regions in the design of assays for adenoma and cancer.